Biotech
-
Jazz names new CEO; Ultragenyx, Mereo shares slide on trial update
Current operations chief Renee Gala will succeed Bruce Cozadd at Jazz. Meanwhile, a key study of an Ultragenyx and Mereo…
Read More » -
With Verona deal, Merck wagers on strength of lung drug’s patents
The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For…
Read More » -
Lilly gets FDA OK of modified dosing for Alzheimer’s drug
A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant…
Read More » -
Medical groups, pregnant doctor sue RFK Jr. over vaccine changes
The complaint argues Kennedy’s actions to remove the COVID vaccine from the CDC's immunization schedule for pregnant people and healthy…
Read More » -
Regeneron bispecific approved for myeloma; Concentra to buy IGM
Lynozyfic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling…
Read More » -
Organon drug for endometriosis falls short in mid-stage study
Company executives had seen the drug as a potential multi-billion dollar opportunity in women’s health.
Read More » -
Atai and Beckley, set to merge, reveal study success for psychedelic drug
Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their…
Read More » -
FDA takes major step to ease access to CAR-T therapy
The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ post-treatment movement.
Read More » -
Biocryst sells Europe business; Peter Marks criticizes new FDA vaccine rules
Biocryst is offloading part of its business for $250 million. Meanwhile, the former FDA leader took issue with a new…
Read More » -
CDC panel, newly remade by RFK Jr., questions vaccine evidence
New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at…
Read More »